View Ocuphire’s Recent Positive Phase 3 Data on Nyxol for Reversal of Mydriasis
Latest Financial Results
Q1 2021
Quarter Ended Mar 31, 2021
Email Alerts
Stay informed and receive company updates straight to your inbox.
Stock Information
Company Overview
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.
Investor Contact Information
Company
Ocuphire Pharma, Inc.
37000 Grand River Ave., Suite 120
Farmington Hills, MI 48335
T: 248-681-9815
ir@ocuphire.com
Investor Relations
LifeSci Advisors
250 West 55th Street, Suite 3401
New York, NY 10019
T: 646-889-1200
cdavis@lifesciadvisors.com
Transfer Agent
American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
www.astfinancial.com